ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Atossa Therapeutics reported a Q2 2026 net loss of $8.49M and diluted EPS of $(0.95). Cash reserves stood at $26.1M, with the company expressing substantial doubt about its ability to continue as a going concern. The firm advanced its (Z)-endoxifen program across four Phase 2 trials, secured orphan drug designations for DMD and MAS, and completed a $4.0M capital raise to support operations.
Atossa Therapeutics, Inc. reported a net loss for the second quarter of 2026, with net loss of $(8.49M) and diluted loss per share of $(0.95). Cash and cash equivalents totaled $26.1M at June 30, 2026, and the company disclosed substantial doubt about its ability to continue as a going concern.
Financial Highlights
- Net income: $(8.49M) loss for Q2 2026, compared with $(8.42M) loss in Q2 2025.
- Diluted EPS: $(0.95) for Q2 2026, versus $(0.98) in the year-ago quarter.
- Cash & liquidity note: Cash and cash equivalents $26.1M at June 30, 2026 (working capital $25.6M); company reports substantial doubt about going concern.
Business Highlights
- Clinical program progress: Advanced (Z)-endoxifen across four Phase 2 trials (Karisma, I-SPY, RECAST, EVANGELINE) with ongoing enrollments and expected data readouts in H2 2026.
- Clinical efficacy signals: Reported biological activity including reduced mammographic breast density, Ki-67 suppression, MRI tumor volume reductions and ctDNA clearance.
- Regulatory & orphan designations: Secured Rare Pediatric Disease and Orphan Drug designations for DMD and a Rare Pediatric Disease designation for MAS, supporting potential PRV value.
- Manufacturing & IP: Established a proprietary manufacturing process, multiple dosage strengths, seven U.S. and 16 international patents with protection through at least 2038.
- Capital raises & runway: Completed a $4.0M registered direct offering and initiated an ATM program to support near-term operations and upcoming trial milestones.
Original SEC Filing: ATOSSA THERAPEUTICS, INC. [ ATOS ] - 10-Q - Aug. 07, 2026